摘要
目的:比较新癀片、美洛昔康片及塞来昔布胶囊治疗急性痛风性关节炎的经济性,为临床决策提供参考与建议。方法:从医疗保健系统出发,通过建立决策树模型对新癀片、美洛昔康片及塞来昔布胶囊治疗方案进行成本效果分析,并针对参数的不确定性进行敏感性分析。结果:美洛昔康片治疗骨质疏松症的总成本为28.06元,新癀片方案的总成本为35.30元,塞来昔布胶囊的总成本为42.22元;美洛昔康片方案的有效率为83.4%,新癀片方案的有效率为97.1%,塞来昔布胶囊方案的有效率为96.1%。与美洛昔康片相比,新癀片治疗急性痛风性关节炎的增量成本效果比为52.83,即每多治愈一位患者,多花费的成本为52.83元。塞来昔布胶囊方案与新癀片方案疗效相当,但成本更高。单因素敏感性分析结果与基础分析结果一致。结论:综合考虑目前患者及家庭的承受能力,新癀片在治疗急性痛风性关节炎方面具有一定的优势。
Objective:The objective of this study was to evaluate the cost effectiveness of Xinhuangtablet,Meloxicam tablet andCelecoxib capsules in the treatment of Acute gouty arthritis in China and to provide clinicians with some advice.Methods:A decision tree model was used to estimate to the cost-effectiveness analysis of Xinhuangtablet,Meloxicam tablet andCelecoxib capsules from the health care system perspective.The parameters uncertainty in the model was estimated through sensitivity analysis.Results:The total cost for Meloxicam tabletgroup,Xinhuangtabletgroup and Celecoxib capsules was￥28.06,￥35.30 and￥42.22.The effective rate of three group was 83.4%,97.1%and 96.1%.The ICER value of Meloxicam tabletgroup and Xinhuangtablet group was 52.83 which means Xinhuangtablet group cost more￥52.83 to cure a patient.Celecoxib capsulesgroup had the same effect as Xinhuangtablet group,but it was more expensive.Result of one-way sensitivity test was same to that of cost-effectiveness analysis.Conclusion:Considering the current economic burdenof patients and families,Xinhuangtablethas advantages in the treatment of Acute gouty arthritis.
作者
陈永法
戈颖莹
雷媛
祁舒
GE Ying-ying;LEI Yuan;Qi Shu;CHEN Yong-fa(School of International Pharmacuetical Business of China Pharmacuetical University,Jiangsu Nanjing 211198,China)
出处
《中国药物评价》
2018年第1期56-61,共6页
Chinese Journal of Drug Evaluation
